Aristotle University Of Thessaloniki (AUTH)
Κλινικοεργαστηριακή μελέτη της ελάχιστα επεμβατικής σε σχέση με τη συμβατική εξωσωματική κυκλοφορία σε χειρουργικές επεμβάσεις αορτοστεφανιαίας παράκαμψης
Abstract
dc:descriptionMinimal extracorporeal circulation (MECC) represents a technologicallyadvanced circuit designed to eliminate adverse effects of cardiopulmonarybypass. The aim of this study is to compare minimal (MECC) versusconventional (CECC) extracorporeal circulation in terms of early postoperativeclinical and laboratory outcome, associated major adverse events and inpromoting fast-track recovery in patients undergoing elective coronary arterybypass grafting. This is a prospective randomized controlled trial including 200 patientsoperated for severe coronary artery disease under extracorporeal circulation atthe Cardiothoracic Department, Aristotle University of Thessaloniki. Group Aincluded 100 patients operated on MECC, while group B consisted of 100patients operated with use of conventional extracorporeal circulation.Regarding fast-track recovery trial, 120 patients (60 in each group) fulfilledinclusion criteria. Both groups were similar in terms of demographics andpreoperative characteristics. Perioperative clinical variables were recordedand analyzed, as well as patients’ haematological profile (Hct, Hb, Plt, LDH),coagulation profile (INR, PT, aPTT), markers indicative of myocardial damage(CK, CK-MB, SGOT), hepatic (SGPT) and renal dysfunction (serumcreatinine). Parameters were assessed: preoperatively (T1), immediately afterthe operation (T2), on the first postoperative day (T3) and on the day ofdischarge (T4). The incidence of major adverse events (postoperativemyocardial infarction, renal failure, stroke, death) was calculated in eachgroup, especially in high-risk patients (age > 65 years, ejection fraction ≤ 40%, EuroSCORE II > 5%). Finally, the rates of successful fast-track recovery (earlyextubation during the first 6 hours and discharge from Cardiac Recovery Unitduring the first 24 hours) were compared between the two subgroups. Use of MECC was associated with shorter duration of cardiopulmonarybypass (p<0.001), CRU stay (p<0.001), duration of mechanical ventilation(p<0.001), reduced incidence of atrial fibrillation (p=0.016) and bloodtransfusion requirements either intraoperatively (p<0.001) or postoperatively(p=0.002). Haematocrit and haemoglobin levels were significantly higheramong patients operated on MECC, together with platelet count. CECC groupwas associated with increased values of LDH postoperatively as well asprolongation of INR, PT and aPTT. Improved myocardial protection wasobserved in MECC group as evidenced by lower levels of CK, CK-MB andSGOT, while hepatic and renal dysfunction characterized patients operated onCECC, as evidenced by the higher levels of SGPT and creatinine. Moreover,MECC group was associated with a significantly lower incidence of majoradverse events (p=0.005), mainly attributed to the lower rates of postoperativemyocardial infarction and renal failure. Use of MECC was related to a 77%relative risk reduction as compared to CECC (OR: 0.230, p=0.004).Furthermore, use of MECC significantly favors high-risk patients by decreasingthe incidence of major adverse events. Regarding fast-track recovery, use ofMECC circuit increased the probability of successful fast-track recovery by 4.7times (OR: 4.700, p=0.006) and was identified as the only independentpositive predictor (OR: 3.800, p=0.011). In conclusion, the results of our study show that use of MECC circuit issuperior to conventional extracorporeal circulation in terms of reducingadverse effects on remote organs. Moreover, the lower incidence of the majoradverse events recorded in patients operated on MECC proves its significantbeneficial impact, specifically in high-risk patients. At the same time, MECCcircuit enhances fast-track recovery of the patients by facilitating early trachealextubation and discharge from Cardiac Recovery Unit. This beneficial effectcould be attributed to advanced technologic properties of the circuit thatincrease its biocompatibility and reduce activation of systemic inflammatoryresponse syndrome.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Asteriou, Christos
- Αστερίου, Χρήστος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/38076